In this episode of Curie, Matt covers three major developments in oncology. The FDA has approved datopotamab deruxtecan (Datroway) for HR positive, HER2 negative breast cancer, marking a new era for antibody-drug conjugates in this disease. A meta-analysis suggests that the timing of immunotherapy infusions may impact survival outcomes, raising questions about how circadian rhythms influence treatment response. Finally, a global analysis confirms that early-onset colorectal cancer is on the rise worldwide, challenging current screening guidelines and prompting discussions on prevention strategies. Tune in for the latest insights shaping cancer care.